scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1013234976 |
P356 | DOI | 10.1186/AR4672 |
P932 | PMC publication ID | 4220089 |
P698 | PubMed publication ID | 25059342 |
P5875 | ResearchGate publication ID | 264246366 |
P50 | author | Jérôme Avouac | Q45580503 |
Jean-François Zagury | Q64750696 | ||
P2093 | author name string | Yannick Allanore | |
Hadley Mouhsine | |||
Hervé Do | |||
Lucille Desallais | |||
Rojo Ratsimandresy | |||
Matthieu Montes | |||
Maxime Fréchet | |||
Muriel Elhai | |||
P2860 | cites work | CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse | Q34792036 |
Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton | Q36077865 | ||
Vaccination with cytokines in autoimmune diseases | Q37165366 | ||
Anti-cytokine therapeutics: history and update | Q37515918 | ||
Animal models of systemic sclerosis: prospects and limitations | Q37771308 | ||
Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. | Q40490993 | ||
Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement | Q40491920 | ||
Relationship between interleukin-6 and cardiac involvement in systemic sclerosis | Q43812359 | ||
Interleukin-1, Interleukin-2, Interleukin-4, Interleukin-6, Tumor Necrosis Factor α, and Interferon-γ Levels in Sera from Patients With Scleroderma | Q44338106 | ||
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. | Q46597820 | ||
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis | Q47763592 | ||
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. | Q53803121 | ||
Scleroderma | Q54165664 | ||
Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. | Q54335579 | ||
Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. | Q54599837 | ||
Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis | Q57265274 | ||
In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease | Q71607968 | ||
Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice | Q72356859 | ||
A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice | Q72680204 | ||
Development of the tight-skin phenotype in immune-deficient mice | Q73661511 | ||
Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis | Q74452502 | ||
Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma | Q77319152 | ||
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis | Q77742326 | ||
Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis | Q78169196 | ||
Connective tissue development in subcutaneously implanted polyvinyl sponge. I. Biochemical changes during development | Q79111307 | ||
Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling | Q80350639 | ||
Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production | Q81714149 | ||
Active immunization against IL-23p19 improves experimental arthritis | Q82081093 | ||
Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma | Q82401401 | ||
[Interactions between fibrillin-1 and tgf-beta: consequences and human pathology] | Q83393406 | ||
Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis | Q83499702 | ||
IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease | Q84586437 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 4 | |
P921 | main subject | immunization | Q1415366 |
active immunization | Q3425478 | ||
P304 | page(s) | R157 | |
P577 | publication date | 2014-07-24 | |
P1433 | published in | Arthritis Research and Therapy | Q15757229 |
P1476 | title | Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis | |
P478 | volume | 16 |
Q40047502 | A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice |
Q45920167 | An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. |
Q39450087 | An update on biomarker discovery and use in systemic sclerosis. |
Q26741264 | Current perspectives on the immunopathogenesis of systemic sclerosis |
Q61445191 | Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches |
Q100559306 | Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis |
Q90363927 | Drugs in phase I and phase II clinical trials for systemic sclerosis |
Q91845024 | Emerging targets of disease-modifying therapy for systemic sclerosis |
Q37611647 | Epigenetic Regulation of Interleukin 6 by Histone Acetylation in Macrophages and Its Role in Paraquat-Induced Pulmonary Fibrosis |
Q49989946 | Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells |
Q37614491 | IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases |
Q36499879 | Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys |
Q58785737 | Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1 |
Q98577683 | Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway |
Q37471585 | Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis |
Q28072568 | Pathophysiology of systemic sclerosis |
Q94219607 | Potential Vaccines for Treating Crohn's Disease |
Q40683161 | Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial |
Q51250934 | Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts. |
Q28073706 | Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis |
Q36682162 | Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways |
Q38636049 | Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy |
Q28072943 | Targeted Therapy in Systemic Sclerosis |
Q89717413 | The mighty fibroblast and its utility in scleroderma research |
Q64940918 | Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. |
Q53165286 | Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. |
Search more.